250 related articles for article (PubMed ID: 15877061)
1. The origins of new drugs.
Kneller R
Nat Biotechnol; 2005 May; 23(5):529-30. PubMed ID: 15877061
[No Abstract] [Full Text] [Related]
2. Pipelines turn to biotech.
Lawrence S
Nat Biotechnol; 2007 Dec; 25(12):1342. PubMed ID: 18066015
[No Abstract] [Full Text] [Related]
3. Biotech drug market steadily expands.
Lawrence S
Nat Biotechnol; 2005 Dec; 23(12):1466. PubMed ID: 16333279
[No Abstract] [Full Text] [Related]
4. The biotech drug market.
Lawrence S
Nat Biotechnol; 2004 Dec; 22(12):1496. PubMed ID: 15583645
[No Abstract] [Full Text] [Related]
5. Public biotech 2009-the numbers.
Huggett B; Hodgson J; Lähteenmäki R
Nat Biotechnol; 2010 Aug; 28(8):793-9. PubMed ID: 20697401
[No Abstract] [Full Text] [Related]
6. Value creation and sharing among universities, biotechnology and pharma.
Edwards MG; Murray F; Yu R
Nat Biotechnol; 2003 Jun; 21(6):618-24. PubMed ID: 12776145
[No Abstract] [Full Text] [Related]
7. Wrong numbers?
Nat Biotechnol; 2010 Aug; 28(8):761. PubMed ID: 20697382
[No Abstract] [Full Text] [Related]
8. Raising the game.
Nat Biotechnol; 2008 Feb; 26(2):137. PubMed ID: 18259155
[No Abstract] [Full Text] [Related]
9. Deconstructing Myogen's market cap.
Ransom J
Nat Biotechnol; 2006 Mar; 24(3):227-8. PubMed ID: 16525363
[No Abstract] [Full Text] [Related]
10. Biotech blockbusters consolidate markets.
Lawrence S
Nat Biotechnol; 2006 Dec; 24(12):1466. PubMed ID: 17160033
[No Abstract] [Full Text] [Related]
11. Public biotechnology 2005--the numbers.
Lähteenmäki R; Lawrence S
Nat Biotechnol; 2006 Jun; 24(6):625-34. PubMed ID: 16763588
[TBL] [Abstract][Full Text] [Related]
12. Academic partnerships 2014.
Huggett B
Nat Biotechnol; 2015 Apr; 33(4):333. PubMed ID: 25850049
[No Abstract] [Full Text] [Related]
13. Trends in antimicrobial drug development: implications for the future.
Spellberg B; Powers JH; Brass EP; Miller LG; Edwards JE
Clin Infect Dis; 2004 May; 38(9):1279-86. PubMed ID: 15127341
[TBL] [Abstract][Full Text] [Related]
14. Benchmarking biotech and pharmaceutical product development.
Drakeman DL
Nat Biotechnol; 2014 Jul; 32(7):621-5. PubMed ID: 25004226
[No Abstract] [Full Text] [Related]
15. Insights into US public biotech sector using patenting trends.
Aggarwal S; Gupta V; Bagchi-Sen S
Nat Biotechnol; 2006 Jun; 24(6):643-51. PubMed ID: 16763590
[TBL] [Abstract][Full Text] [Related]
16. Recombinant protein therapeutics--success rates, market trends and values to 2010.
Pavlou AK; Reichert JM
Nat Biotechnol; 2004 Dec; 22(12):1513-9. PubMed ID: 15583654
[No Abstract] [Full Text] [Related]
17. Public biotech 2006 - the numbers.
Lähteenmäki R; Lawrence S
Nat Biotechnol; 2007 Jul; 25(7):729-37. PubMed ID: 17621294
[No Abstract] [Full Text] [Related]
18. Public biotech 2010--the numbers.
Huggett B; Hodgson J; Lähteenmäki R
Nat Biotechnol; 2011 Jul; 29(7):585-91. PubMed ID: 21747381
[No Abstract] [Full Text] [Related]
19. Biopharmaceutical benchmarks--2003.
Walsh G
Nat Biotechnol; 2003 Aug; 21(8):865-70. PubMed ID: 12894198
[No Abstract] [Full Text] [Related]
20. Advice for partnering with pharma.
Howard K
Nat Biotechnol; 2004 Nov; 22(11):1477-9. PubMed ID: 15586421
[No Abstract] [Full Text] [Related]
[Next] [New Search]
